Gene-based outcome prediction in multiple cohorts of pediatric T-cell acute lymphoblastic leukemia: a Children's Oncology Group study.
BACKGROUND
Continuous complete clinical remission in T-cell acute lymphoblastic leukemia (T-ALL) is now approaching 80% due to the implementation of aggressive chemotherapy protocols but patients that relapse continue to have a poor prognosis. Such patients could benefit from augmented therapy if their clinical outcome could be more accurately predicted at the time of diagnosis. Gene expression profiling offers the potential to identify additional prognostic markers but has had limited success in generating robust signatures that predict outcome across multiple patient cohorts. This study aimed to identify robust gene classifiers that could be used for the accurate prediction of relapse in independent cohorts and across different experimental platforms.


RESULTS
Using HG-U133Plus2 microarrays we modeled a five-gene classifier (5-GC) that accurately predicted clinical outcome in a cohort of 50 T-ALL patients. The 5-GC was further tested against three independent cohorts of T-ALL patients, using either qRT-PCR or microarray gene expression, and could predict patients with significantly adverse clinical outcome in each. The 5-GC featured the interleukin-7 receptor (IL-7R), low-expression of which was independently predictive of relapse in T-ALL patients. In T-ALL cell lines, low IL-7R expression was correlated with diminished growth response to IL-7 and enhanced glucocorticoid resistance. Analysis of biological pathways identified the NF-kappaB and Wnt pathways, and the cell adhesion receptor family (particularly integrins) as being predictive of relapse. Outcome modeling using genes from these pathways identified patients with significantly worse relapse-free survival in each T-ALL cohort.


CONCLUSIONS
We have used two different approaches to identify, for the first time, robust gene signatures that can successfully discriminate relapse and CCR patients at the time of diagnosis across multiple patient cohorts and platforms. Such genes and pathways represent markers for improved patient risk stratification and potential targets for novel T-ALL therapies.
Cleaver
Amanda L
AL
Division of Children's Leukaemia and Cancer Research, Telethon Institute for Child Health Research, Perth, Australia.
Beesley
Alex H
AH
Firth
Martin J
MJ
Sturges
Nina C
NC
O'Leary
Rebecca A
RA
Hunger
Stephen P
SP
Baker
David L
DL
Kees
Ursula R
UR
D000293:Adolescent; D000465:Algorithms; D014408:Biomarkers, Tumor / Q000032:analysis / Q000235:genetics*; D002648:Child; D002675:Child, Preschool; D003663:Decision Trees; D005260:Female; D015870:Gene Expression; D020869:Gene Expression Profiling / Q000379:methods*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D016328:NF-kappa B / Q000235:genetics; D020411:Oligonucleotide Array Sequence Analysis; D054218:Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics* / Q000401:mortality; D011379:Prognosis; D020395:Receptors, Interleukin-7 / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016896:Treatment Outcome; D051153:Wnt Proteins / Q000235:genetics
D014408:Biomarkers, Tumor; D016328:NF-kappa B; D020395:Receptors, Interleukin-7; D051153:Wnt Proteins
Blood. 2008 May 1;111(9):4477-89
18285545
Leukemia. 2003 May;17(5):887-93
12750702
J Biol Chem. 2001 Aug 17;276(33):31285-95
11371555
Clin Cancer Res. 2005 Nov 1;11(21):7851-60
16278408
Blood. 2003 Oct 15;102(8):2951-9
12730115
Nucleic Acids Res. 2003 Feb 15;31(4):e15
12582260
Cell. 2000 Jan 7;100(1):57-70
10647931
BMC Cancer. 2006 Sep 26;6:229
17002788
PLoS Med. 2006 Mar;3(3):e47
16417408
J Clin Oncol. 2003 Oct 1;21(19):3616-22
14512392
Leukemia. 2006 Jul;20(7):1197-205
16688226
Leukemia. 1999 Nov;13(11):1696-707
10557041
Leukemia. 2008 Dec;22(12):2142-50
18818707
Leukemia. 2007 Jun;21(6):1198-203
17410184
J Immunol. 2007 Apr 15;178(8):5132-43
17404296
BMC Genomics. 2005 Apr 27;6:59
15854232
Cancer Cell. 2002 Mar;1(2):133-43
12086872
Br J Haematol. 2005 Nov;131(4):447-56
16281934
Cytokine Growth Factor Rev. 2005 Aug-Oct;16(4-5):513-33
15996891
Leuk Lymphoma. 2005 Apr;46(4):483-95
16019476
Prostate. 2007 Jun 15;67(9):955-67
17440963
Nature. 2009 Jun 18;459(7249):1000-4
19536265
Lancet Oncol. 2009 Feb;10(2):147-56
19147408
Blood. 2007 Sep 1;110(5):1429-38
17495134
Blood. 2008 Mar 1;111(5):2548-55
18039957
Cancer Sci. 2004 May;95(5):385-92
15132764
Oncogene. 1995 Oct 5;11(7):1333-8
7478554
Blood. 2002 Jun 1;99(11):4109-15
12010814
Br J Cancer. 2009 Jun 16;100(12):1926-36
19436302
Nat Med. 2007 Jan;13(1):70-7
17173050
Br J Haematol. 2008 Mar;140(6):656-64
18302714
Blood. 2002 Aug 1;100(3):991-7
12130513
Oncogene. 2006 May 25;25(22):3113-22
16407823
Blood. 2000 Jul 1;96(1):297-306
10891465
J Clin Oncol. 2006 Dec 20;24(36):5742-9
17179108
BMC Bioinformatics. 2005 Apr 13;6:97
15826317
Lancet. 2008 Mar 22;371(9617):1030-43
18358930
Cancer Cell. 2002 Feb;1(1):75-87
12086890
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
16199517
J Cell Sci. 2000 Jul;113 ( Pt 13):2385-97
10852818
Br J Cancer. 2006 Dec 4;95(11):1537-44
17117183
Leukemia. 2009 Jan;23(1):43-52
18987663
Nat Rev Mol Cell Biol. 2004 Oct;5(10):816-26
15459662
Cancer Res. 2004 Apr 15;64(8):2898-903
15087409
Blood. 2009 Jul 30;114(5):1053-62
19406988
Clin Cancer Res. 2008 Dec 1;14(23):7924-9
19047123
Blood. 2007 Oct 1;110(7):2324-30
17609427
Br J Haematol. 2007 May;137(4):319-28
17456054